myosin inhibitor
Bayer Secures Exclusive Rights to Aficamten in Japan Through Licensing Agreement with Cytokinetics
Bayer, Cytokinetics, Aficamten, Japan, Licensing Agreement, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor
Actionable Insights Powered by AI
Bayer, Cytokinetics, Aficamten, Japan, Licensing Agreement, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor